Yarrow Bioscience (YARW) 3rd Annual Guggenheim Healthcare Innovation Conference summary
Event summary combining transcript, slides, and related documents.
3rd Annual Guggenheim Healthcare Innovation Conference summary
9 Nov, 2026Strategic rationale and market
YB-101 is a monoclonal antibody designed to block TSHR directly, targeting the disease pathway in both Graves’ disease and thyroid eye disease (TED).
Graves’ disease and TED are driven by autoantibodies that overstimulate TSHR in the thyroid and eye; the disease is polyclonal, with varied antibody isotypes.
TSHR blockade may address both thyroid and eye disease; IGF-1R inhibitors validate the potential for eye improvement but are limited by safety concerns and do not address thyroid disease.
Graves’ disease affects 1% of the U.S. population; 40% of patients develop TED, and 20%-25% develop moderate-to-severe TED requiring intervention.
Development aims to enable broad, potentially earlier treatment; the TED goal is IGF-1R-like efficacy with a more favorable risk-benefit profile.
Clinical evidence and safety
China Phase I single-ascending-dose TED study showed favorable safety, with no dose-limiting toxicities; thyroid hormone changes were the main safety difference from placebo.
After a single dose, T4 and T3 declined within 2-3 days and TSH increased within 5 days, indicating rapid reversal of thyroid hormone balance.
Small-sample Phase I data showed dose-dependent proptosis responses differentiated from placebo, viewed as proof of mechanism and support for multiple-dose evaluation.
Hypothyroidism is expected on-target pharmacology; prompt T4 replacement is intended to make it transient while maintaining normal thyroid hormone levels.
For Graves’ disease, management views the uncontrolled FcRn study’s 56% euthyroid/off-ATD result as a reference point and aims to do better; TED aspirations target IGF-1R-like efficacy.
Graves’ and TED development plans
Direction GD Phase II-A is a four-cohort, placebo-controlled study with dosing every 8 weeks; the 6-month primary endpoint is the proportion euthyroid and off antithyroid drugs (ATDs).
Participants must have stable thyroid function on ATDs for at least 3 months; the protocol uses a structured ATD taper and initiates T4 based on thyroid hormone changes.
Initial cohorts use 180 mg and 270 mg every 8 weeks; tentative later cohorts are 400 mg every 8 weeks and 200 mg every 4 weeks, subject to data review.
First patient was dosed in July; Phase II-A data are expected in 2H 2027, with all four cohorts planned for a combined disclosure.
China TED Phase I-B multiple-ascending-dose data are expected in 2H 2027; Phase II-B Graves’ doses will be selected using Phase II-A results.
Latest events from Yarrow Bioscience
- YB-101 targets TSHR across GD and TED, with key clinical data expected in 2027.YARW
Investor presentation - DIRECTION-GD and GenSci TED data are expected in H2 2027; cash runway extends into 2030.YARW
Q3 2026 - Merger completed, $200M raised, YB-101 trial advanced, and Q2 net loss was $6.5M.YARW
Q2 2026 - YB-101 targets unmet needs in GD and TED with a novel, well-funded, and differentiated approach.YARW
Investor presentation - Advancing BET inhibitors for autoimmune diseases with robust trials and strong financial runway.YARW
Stifel 2024 Immunology and Inflammation Virtual Summit - Net loss narrowed 58% year-over-year as R&D spending dropped ahead of the Yarrow merger.YARW
Q1 2026 - Losses narrowed in 2025 as the company pivots to a merger with Yarrow and exits key R&D programs.YARW
Q4 2025 - BET inhibitor programs advance in vitiligo and psoriasis, with key clinical readouts expected in 2024.YARW
H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - BET inhibitor programs advance in vitiligo and psoriasis, with pivotal data expected in 2024–2025.YARW
TD Cowen 45th Annual Healthcare Conference